Henrik Watz, MD, PhD, has been named a 2024 Top Scholar by ScholarGPS, ranked #34 globally among chronic obstructive pulmonary disease (COPD) researchers over the past five years, and recognized among the top 0.5% of all researchers worldwide.
Over the past year, Dr. Watz has:
- Presented compelling real-world data at ATS 2025 on the long-term impact of dupilumab therapy in severe asthma (with more than half of participants achieving asthma remission within two years).
- Spoke at the 2024 DGP Congress in Leipzig, Germany, on advances in pneumology research.
- Delivered a featured presentation at the 2024 ERS ADVENT COPD Symposia on Type 2 inflammation in COPD.
- Led a global COPD trial at his site in Ahrensburg, Germany, which more than doubled the enrollment of the next highest-performing site.
- Was recognized as the top enroller for another global COPD trial at the Ahrensburg site.
- Published his 250th full paper, detailing findings from the Phase 2 AIRLEAF trial for bronchiectasis (his team also served as the central sputum lab for the study).
- Participated in 10 presentations at ERS Congress 2023, and introduced the Sanofi Regeneron symposium, “A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation.”
- Presented on a first-in-class COPD medication: a modified macrolide developed by EpiEndo Pharmaceuticals.
Congratulations to Dr. Watz and our team in Ahrensburg!
